Guselkumab in moderate to severe psoriasis in routine clinical care: an Italian 44-week real-life experience
Matteo Megna, Gabriella Fabbrocini, Eleonora Cinelli, Elisa Camela, Angelo Ruggiero
Abstract
Objectives We aimed to evaluate the effectiveness, safety and tolerability of guselkumab in a real-life setting.Methods A prospective, observational, single-center, real-life study including patients under guselkumab treatment from October 2018 to January 2020 was conducted.Results Twenty-three patients with moderate-to-severe psoriasis were enrolled and twenty-two continued the treatment until week 44. One patient discontinued for increase in liver enzymes. At baseline, mean PASI score was 15.1 ± 6.1, which reduced up to 3.2 ± 1.9 at week 12 (p < .001) and 0.8 ± 0.7 at week 44 (p < .001). BSA reduced from 36.4 ± 13.6 at baseline, to 8.3 ± 7.4 at week 12 (p < .001), up to 2.2 ± 1.4 at week 44 (p < .001). A total of 4 patients (17.4%) experienced mild blood tests alterations and 6 subjects (26%) experienced potential adverse events (AEs). No AEs required guselkumab discontinuation. No cases of serious AEs, injection site reaction, candida, malignancy, cardiovascular events were reported.Conclusions Patients under guselkumab therapy reach an optimal clinical response, even in a real-life and long-term setting.